1. Home
  2. NCTY vs LONA Comparison

NCTY vs LONA Comparison

Compare NCTY & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The9 Limited American Depository Shares

NCTY

The9 Limited American Depository Shares

HOLD

Current Price

$5.20

Market Cap

80.2M

ML Signal

HOLD

LONA

LeonaBio Inc. Common Stock

N/A

Current Price

$9.82

Market Cap

90.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCTY
LONA
Founded
1999
2011
Country
China
United States
Employees
N/A
19
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.2M
90.4M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
NCTY
LONA
Price
$5.20
$9.82
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
28.3K
35.8K
Earning Date
03-27-2015
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.00
$4.21
52 Week High
$11.60
$14.21

Technical Indicators

Market Signals
Indicator
NCTY
LONA
Relative Strength Index (RSI) 42.84 49.10
Support Level $5.05 $8.10
Resistance Level $5.91 $9.88
Average True Range (ATR) 0.39 1.04
MACD -0.06 -0.10
Stochastic Oscillator 6.63 38.48

Price Performance

Historical Comparison
NCTY
LONA

About NCTY The9 Limited American Depository Shares

The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Online game services, out of which Crypto mining business derives maximum revenue.

About LONA LeonaBio Inc. Common Stock

LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.

Share on Social Networks: